AmyPore combines in silico and biophysical methods to design adaptive therapeutic peptides for diseases with high unmet medical needs.
Our vision: to become the benchmark for peptide-based treatments of proteinopathies.
AmyPore has designed an exclusive peptide platform that generates a portfolio of adaptive therapeutic peptides. Their unique design enables them to target mechanisms shared by many diseases.
Our peptides change shape on contact with their targets, giving them unprecedented biochemical and pharmacological properties.
This flexibility gives them strong resistance to proteolytic degradation.
They target gangliosides, plasma membrane microdomains recognised by many pathogens and by intrinsically disordered proteins (IDPs), which cause many diseases.
Over 30 years of expertise in IDP modelling, independent of crystallographic structures and AlphaFold.
Mimicking the conformational flexibility of the IDP to neutralise its toxic effects without affecting its physiological roles. A strategy beyond the reach of approaches based on conventional docking or AlphaFold.
“Target the target, not the arrow”Fantini et al., Pharmacology & Therapeutics, 2025
Proprietary algorithms and unique experimental approaches: simulations in silico, biophysical techniques, calcium imaging and cellular models.
Beyond Alzheimer’s and Parkinson’s, our platform has already generated new candidates, notably in oncology and metabolism.
POC: proof of concept. Next step: Phase 1 clinical trial.
